|
a)
|
Adults with RET fusion-positive, advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥ 50 % of tumour cells; first-line therapy
|
Pembrolizumab as monotherapy
|
|
b)
|
Adults with RET fusion-positive, advanced non-small cell lung cancer (NSCLC) with PD-L1 expression < 50% of tumour cells; first-line therapy.
|
Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or - carboplatin in combination with nab-paclitaxel or
- Pembrolizumab in combination with pemetrexed and platinum-containing chemotherapy (only for patients without EGFR- or ALK-positive tumour mutations and with non-squamous histology) or pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel (only with squamous histology) or - monotherapy with gemcitabine or vinorelbine (only for patients with ECOG performance status 2 as an alternative to platinum-based combination treatment)
|
|
c)
|
Adults with RET fusion-positive advanced non-small cell lung cancer (NSCLC) after first-line therapy with a PD-1/PD-L1 antibody as monotherapy.
|
Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or - carboplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or - carboplatin in combination with nab-paclitaxel or Monotherapy with gemcitabine or vinorelbine (only for patients with ECOG performance status 2 as an alternative to platinum-based combination treatment)
|
|
d)
|
Adults with RET fusion-positive advanced non-small cell lung cancer (NSCLC) after first-line therapy with cytotoxic chemotherapy.
|
Docetaxel (only for patients with PD-L1 negative tumours) or - Pemetrexed (only for patients with PD-L1 negative tumours and except in the case of predominantly squamous histology) or - Nivolumab or - pembrolizumab (only for patients with PD-L1 expressing tumours, PD-L1 tumours, PD-L1 expression ≥ 1 % of tumour cells) or - atezolizumab or - Docetaxel in combination with nintedanib (only for patients with PDL1 negative tumours and adenocarcinoma histology).
|
|
e)
|
Adults with RET fusion-positive advanced non-small cell lung cancer (NSCLC); after first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy.
|
Patient-specific therapy with selection of
- afatinib
- pemetrexed
- erlotinib
- docetaxel
- Docetaxel in combination with ramucirumab
- Docetaxel in combination with nintedanib
- vinorelbine
taking into account previous therapy and histology
|
